Raed A. Dweik, M.D.

Staff

Director, Pulmonary Vascular Program

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Location: NB2-106
Email: dweikr@ccf.org
Phone: (216) 445-6542
Fax: (216) 445-8160

 


Nitric oxide (NO) is endogenously synthesized by nitric oxide synthases (NOSs) which convert L-arginine to L-citrulline and NO in the presence of oxygen and several cofactors. Once produced, NO is freely diffusible and enters target cells and into the airway and can be detected in exhaled breath of all humans. NO is formed in high concentrations in the upper respiratory tract (nasopharynx and paranasal sinuses). Our studies have also conclusively demonstrated that the lower respiratory tract is a significant source of NO in exhaled breath. We have also demonstrated that endogenous NO levels in the lung change rapidly in direct proportion to inspired oxygen which strongly supports a critical role for NO as mediator of ventilation-perfusion coupling in the lung. NO also plays a major role in the pathophysiology of pulmonary hypertension (PH), a group of diseases characterized by high pulmonary artery pressures and pulmonary vascular resistance. Our studies have shown that patients with idiopathic pulmonary arterial hypertension (IPAH, previously known as primary pulmonary hypertension or PPH) have low levels of NO in their exhaled breath that increase after initiation of vasodilator therapy. The goal of our current studies is to understand the role of nitric oxide (and other markers in exhaled breath) in lung physiology and in the pathophysiology of lung diseases like pulmonary hypertension and asthma.


Kulwant Singh Aulak  PhD Kulwant Singh Aulak, PhD
Project Staff
Location:NB2-107
Phone:(216) 445-2764
aulakk@ccf.org
Brittany  Brauer  MS Brittany Brauer, MS
Research Technician
Location:NB2-107
Phone:(216) 445-6542
brauer@ccf.org
Chazity  Bush  BS Chazity Bush, BS
Research Coordinator
Location:A50-
Phone:(216) 444-7960
bushc@ccf.org
Charles  Casa  BS Charles Casa, BS
Research Technician
Location:NB2-107
Phone:(216) 445-6542
casac@ccf.org
David   Grove  PhD David Grove, PhD
Senior Research Technologist
Location:A5-415
Phone:(216) 445-4388
groved2@ccf.org
Celia  Melillo  Celia Melillo
Research Coordinator
Location:NB2-107
Phone:(216) 445-6542
melillc@ccf.org
Jennie E. Newman  Jennie E. Newman
Research LPN
Location:A9-424
Phone:(216) 444-7950
newmanj3@ccf.org
Deborah  Paul  MS Deborah Paul, MS
Research Coordinator
Location:NE4-252A
Phone:(216) 444-8460
pauld@ccf.org
Liping  Tian  BS Liping Tian, BS
Senior Research Technologist
Location:NC2-134
Phone:(216) 445-6542
tianl@ccf.org

Dweik RA, et.al. NO synthesis in the lung. JCI 1998. Dweik RA, et.al. NO Chemical Events in the Human Airway During Antigen-Induced Asthmatic Response. PNAS 2001. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet 2002.Dweik RA. Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly! Thorax 2005.(Dweik RA, contributing author). ATS Recommendations for Standardized Procedures for Exhaled Nitric Oxide 2005. AJRCCM 2005.Dweik RA. The lung in the balance: arginine, methylated arginines, and nitric oxide. AJP Lung 2007.


01/03/2019 |  

The Search for Causes of Idiopathic Pulmonary Arterial Hypertension

Pulmonary hypertension is considered the final common pathway of many varied diseases and syndromes, and therefore one cannot say it is idiopathic without making a robust effort to identify features of alternative causes and rule our other contributing factors. Akshay Bhatnegar, MD, staff in Department of Regional Anesthesiology, Raed Dweik, MD, Chair of the Respiratory Institute, and Neal Chaisson, MD, staff in the Departments of Pulmonary and Critical Care Medicine and the Respiratory Institute, authored an article published in the Cleveland Clinic Journal of Medicine which offers a case-based guide to evaluating patients with suspected pulmonary arterial hypertension (PAH).